Effects of intravenous iron on fibroblast growth factor 23 (FGF23) in haemodialysis patients: a randomized controlled trial.

BMC Nephrol 2016 11 16;17(1):177. Epub 2016 Nov 16.

Eastern Health Clinical School, Monash University, Box Hill, VIC, Australia.

Background: Intravenous iron affects serum levels of intact fibroblast growth factor-23 (iFGF23) and its cleavage product c-terminal FGF23 (cFGF23) in iron-deficient people with normal renal function. We hypothesized that intravenous iron modulates iFGF23 and cFGF23 in haemodialysis patients differently according to the type of iron used.

Methods: Prevalent, stable haemodialysis patients requiring protocol-based intravenous iron therapy were randomized to a single 200 mg dose of either ferric carboxymaltose (FCM) or iron sucrose (IS). The primary outcome was change in iFGF23 and cFGF23 from pre-infusion to Day 2 post-infusion. Serum hepcidin, ferritin and phosphate were also measured. Pair-wise comparisons utilised the Wilcoxon rank sum test; linear mixed models with an interaction term for treatment and time evaluated between-group effects.

Results: Forty-two participants completed the study. In those randomized to FCM (n = 22), median (interquartile range) values pre-infusion and Day 2, respectively, were 843 pg/mL (313-1922) and 576 pg/mL (356-1296, p = 0.05) for iFGF23, 704RU/mL (475-1204) and 813RU/mL (267-1156, p = 0.04) for cFGF23, and 1.53 mmol/L (1.14-1.71) and 1.37 (1.05-1.67, p = 0.03) for phosphate. These parameters did not change following IS. Both serum ferritin (p < 0.001) and hepcidin (p < 0.001) increased in both groups, and the increase in hepcidin was greater in the FCM group (p = 0.03 for between-group difference).

Conclusions: Contrary to iron-deficient people with normal renal function, haemodialysis patients given protocol-driven intravenous FCM demonstrated a fall in iFGF23 and a rise in cFGF23, changes not evident with IS. This suggests a differential effect of intravenous iron treatment according to both formulation and renal function.

Trial Registration: Australian and New Zealand Clinical Trials Register ACTRN12614000548639 . Registered 22 May 2014 (retrospectively registered).

Download full-text PDF

Source
http://dx.doi.org/10.1186/s12882-016-0391-7DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5112660PMC
November 2016
24 Reads

Publication Analysis

Top Keywords

intravenous iron
16
haemodialysis patients
12
ifgf23 cfgf23
8
fibroblast growth
8
pre-infusion day
8
iron
6
ferritin phosphate
4
utilised wilcoxon
4
comparisons utilised
4
measured pair-wise
4
wilcoxon rank
4
phosphate measured
4
pair-wise comparisons
4
sum test
4
interaction term
4
term treatment
4
treatment time
4
models interaction
4
mixed models
4
hepcidin ferritin
4

References

(Supplied by CrossRef)

T Isakova et al.
Kidney Int 2011

OM Gutierrez et al.
N Engl J Med 2008

T Isakova et al.
JAMA 2011

M Wolf et al.
Curr Opin Nephrol Hypertens 2014

EG Farrow et al.
Proc Natl Acad Sci 2011

VH Haase et al.
Blood Rev 2013

V David et al.
Kidney Int 2015

DM Charytan et al.
J Am Soc Nephrol 2015

WC Winkelmayer et al.
JAMA Intern Med 2014

BJ Schouten et al.
Ann Clin Biochem 2009

Y Shimizu et al.
Bone 2009

Similar Publications